AI
RYTM icon

Atom Investors’s Rhythm Pharmaceuticals RYTM Stock Holding History

Atom Investors’s Portfolio RYTM Stock Details RYTM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$4.96M Buy
57,000
+34,071
+149% +$3.31M 0.36% 79
2025
Q4 		$2.45M Buy
+22,929
New +$2.43M 0.19% 166
2025
Q3 		– Sell
-14,866
Closed -$939K – 785
2025
Q2 		$939K Sell
14,866
-96
-0.6% -$5.88K 0.08% 257
2025
Q1 		$793K Buy
14,962
+3,357
+29% +$186K 0.1% 240
2024
Q4 		$650K Buy
+11,605
New +$641K 0.08% 292
2024
Q3 		– Sell
-26,629
Closed -$1.09M – 587
2024
Q2 		$1.09M Sell
26,629
-14,647
-35% -$585K 0.11% 235
2024
Q1 		$1.79M Buy
41,276
+16,345
+66% +$715K 0.22% 157
2023
Q4 		$1.15M Buy
24,931
+5,545
+29% +$175K 0.2% 169
2023
Q3 		$444K Buy
+19,386
New +$434K 0.1% 252

Other funds holding RYTM

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

Atom Investors's RYTM Position: Q1 2026 in Review

Atom Investors increased its Rhythm Pharmaceuticals (RYTM) stake by 149% in Q1 2026, buying an estimated $3.31M and bringing the position to 57,000 shares worth $4.96M. The position accounts for 0.36% of the portfolio, ranked #79.

Atom Investors first reported a position in RYTM in Q3 2023 and has held it in 9 quarters since. 285 funds tracked by Wall St. Rank hold RYTM as of Q1 2026.

  • Atom Investors held 57,000 shares of Rhythm Pharmaceuticals worth $4.96M as of Q1 2026.
  • Atom Investors bought 34,071 Rhythm Pharmaceuticals shares in Q1 2026, an estimated $3.31M.
  • Rhythm Pharmaceuticals made up 0.36% of Atom Investors's portfolio in Q1 2026, its #79 holding.
  • Atom Investors first reported a position in Rhythm Pharmaceuticals in Q3 2023 and has held it in 9 quarters since.
  • 285 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q1 2026.

Based on Atom Investors's 13F filing for Q1 2026, filed 15 May 2026.